Author

A. Bruna

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Research Focus:cell type annotation· 4 Organism:human· 4 Approach:statistical model· 3 Research Focus:clustering· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2

Frequent Co-Authors

A. Shea· 2 shared S. Hamer· 2 shared A. Allo Anido· 1 shared A. De Jaime-Soguero· 1 shared A. G. Martin· 1 shared A. Giovannetti· 1 shared A. Martinez-Aranda· 1 shared A. Nagano· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Shea

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Chemotherapy-treated breast cancer cells activate the Wnt signaling pathway to enter a diapause-DTP state.

F. Lluis, Y. Ellaithy, W. A. Abreu de Oliveira, A. Pabba, A. Qualizza, F. Richard, P. Athanasouli, C. R. Luci, W. De Wispelaere, L. Mourao, S. Hamer, S. Moens, A. De Jaime-Soguero, M. Francesca Baietti, S. J. Hutten, , D. Annibali

This study shows chemotherapy induces a Wnt-active diapause-DTP state in breast cancer cells, which can be targeted by combined Wnt and chemotherapy inhibition.

bioRxiv · Mar 8, 2024 · PreprintCancer Biology

Environment-Dependent Modes of Adaptive Evolution in Neuroblastoma: Plasticity as a Selectable Trait

C. Roux, S. Hamer, A. Shea, E. Chen, A. S. Sadr, C. English, A. Allo Anido, H. Che, B. Geoerger, L. Chesler, G. Schleiermacher, M. D. Morgan, A. Bruna

This study identifies three modes of plasticity in neuroblastoma that shape tumour evolution under selective pressures and therapy resistance.

bioRxiv · Dec 7, 2023 · PreprintCancer Biology

Modelling drug responses and evolutionary dynamics using triple negative breast cancer patient-derived xenografts

A. Shea, Y. Eyal-Lubling, D. Guerrero-Romero, R. Manzano Garcia, W. Greenwood, M. O'Reilly, D. Georgopoulou, M. Callari, G. Lerda, S. Wix, A. Giovannetti, R. Masina, E. Esmaeilishirazifard, A. G. Martin, A. Nagano, , A. Bruna

This paper uses TNBC patient-derived xenografts to model drug responses and evolutionary dynamics, revealing a novel mechanism of olaparib response and synergistic effects with salinomycin.

bioRxiv · Jan 10, 2023 · PreprintCancer Biology

RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and a therapeutic target in patient-derived xenografts

M. Ciscar, E. M. Trinidad, H. Perez-Montoyo, M. Alsaleem, M. J. Jimenez-Santos, M. Toss, A. Sanz-Moreno, A. Vethencourt, G. Perez-Chacon, A. Petit, M. T. Soler-Monso, J. Gomez-Miragaya, C. Gomez-Aleza, M. Jimenez, L. E. Dobrolecki, , E. Gonzalez-Suarez

This study shows RANK is a poor prognosis biomarker in ER-negative breast cancer and that targeting RANK improves outcomes in patient-derived xenografts.

bioRxiv · Dec 13, 2021 · PreprintCancer Biology